Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
Were Expert Investors Right About Insulet Corporation (PODD)?
04:37pm, Monday, 07'th Feb 2022 Insider Monkey
Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.
BellRing Brands (BRBR) Beats Q1 Earnings and Revenue Estimates
11:25pm, Thursday, 03'rd Feb 2022 Zacks Investment Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 8.70% and 1.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
03:04pm, Thursday, 03'rd Feb 2022 Benzinga
Upgrades
BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago quarter EPS of $0.17. The stock
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
03:05pm, Wednesday, 02'nd Feb 2022 Benzinga
Upgrades
Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09 in the year-ago quarter. At
Insulet upgraded at Oppenheimer despite recent surge on FDA approval for Omnipod 5
04:46pm, Monday, 31'st Jan 2022 Seeking Alpha
Following more than 18% rise on Friday in reaction to its announcement on the FDA approval of Omnipod 5, Insulet <> is extending gains after Oppenheimer upgraded the stock
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
03:28pm, Monday, 31'st Jan 2022 Benzinga
Upgrades
UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago quarter EPS of $2.25.
Here's Why Insulet Stock Is Jumping Higher on Friday
05:20pm, Friday, 28'th Jan 2022 The Motley Fool
After some upsetting delays, the FDA has finally approved a key new product.
Here's Why Insulet Stock Is Jumping Higher on Friday
12:20pm, Friday, 28'th Jan 2022
After some upsetting delays, the FDA has finally approved a key new product.
FDA clears Insulet''s Omnipod 5 automated insulin delivery system
11:32am, Friday, 28'th Jan 2022 Seeking Alpha
Insulet (PODD) has received clearance from the FDA for its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged six years and older with type 1 diabetes
Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control
11:00am, Friday, 28'th Jan 2022 Kwhen Finance
CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
03:16pm, Wednesday, 12'th Jan 2022 Kwhen FinanceCORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
10:16am, Wednesday, 12'th Jan 2022
ACTON, Mass.--(BUSINESS WIRE)--Headline of release should read: Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 (instead of Insulet to Announce Fourth Quar
Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021
06:00am, Wednesday, 12'th Jan 2022
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Here's Why You Should Hold on to Insulet (PODD) Stock for Now
01:20pm, Monday, 13'th Dec 2021 Zacks Investment Research
Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.
Here's Why You Should Hold on to Insulet (PODD) Stock for Now
09:59am, Monday, 13'th Dec 2021
Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.
